Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma

被引:27
|
作者
Tsuda, Y. [1 ]
Tsoi, K. [1 ]
Parry, M. C. [1 ]
Stevenson, J. D. [1 ]
Fujiwara, T. [1 ]
Sumathi, V [1 ]
Jeys, L. M. [1 ]
机构
[1] Royal Orthopaed Hosp, Dept Oncol, Birmingham, W Midlands, England
来源
BONE & JOINT JOURNAL | 2020年 / 102B卷 / 06期
关键词
HIGH-DOSE METHOTREXATE; NONMETASTATIC OSTEOSARCOMA; NEOADJUVANT CHEMOTHERAPY; HISTOLOGIC RESPONSE; OSTEOGENIC-SARCOMA; PROGNOSTIC-FACTORS; DELAYED SURGERY; EXTREMITIES; EURAMOS-1; CISPLATIN;
D O I
10.1302/0301-620X.102B6.BJJ-2019-1307.R1
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Aims To assess the correlation between the histological response to preoperative chemotherapy and event-free survival (EFS) or overall survival (OS) in patients with high-grade localized osteosarcoma. Methods Out of 625 patients aged <= 40 years treated for primary high-grade osteosarcoma between 1997 and 2016, 232 patients without clinically detectable metastases at the time of diagnosis and treated with preoperative high-dose methotrexate, adriamycin and cisplatin (MAP) chemotherapy and surgery were included. Associations of chemotherapy-induced necrosis in the resected specimen and EFS or OS were assessed using Cox model and the Pearson's correlation coefficients (r). Time-dependent receiver operating characteristic analysis was applied to determine the optimal cut-off value of chemotherapy-induced necrosis for EFS and OS. Results OS was 74% (95% confidence interval (CI) 67 to 79) at five years. Median chemotherapy- induced necrosis was 85% (interquartile range (KIR) 50% to 97%). In multivariate Cox model, chemotherapy-induced necrosis was significantly associated with EFS and OS (hazard ratio (HR) = 0.99 (95% CI 0.98 to 0.99); p < 0.001 and HR = 0.98 (95% CI 0.97 to 0.99); p < 0.001, respectively). Positive correlation was observed between chemotherapy-induced necrosis and five-year EFS and five-year OS (r = 0.91; p < 0.001, and r = 0.85; p < 0.001, respectively). The optimal cut-off value of chemotherapy-induced necrosis for five-year EFS and five-year OS was 85% and 72%, respectively. Conclusion Chemotherapy-induced necrosis in the resected specimen showed positive correlation with EFS and OS in patients with high-grade localized osteosarcoma after MAP chemotherapy. In our analysis, optimal cut-off values of MAP chemotherapy-induced necrosis in EFS and OS were lower than the commonly used 90%, suggesting the need for re-evaluation of the optimal cut-off value through larger, international collaborative research.
引用
收藏
页码:795 / 803
页数:9
相关论文
共 50 条
  • [31] Chemotherapy-induced amenorrhea: Influence on disease-free survival and overall survival in receptor positive premenopausal early breast cancer patients.
    Vanhuyse, M
    Fournier, C
    Bonneterre, ME
    Bonneterre, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 90S - 90S
  • [32] Chemotherapy-induced amenorrhea: influence on disease-free survival and overall survival in receptor-positive premenopausal early breast cancer patients
    Vanhuyse, M
    Fournier, C
    Bonneterre, J
    ANNALS OF ONCOLOGY, 2005, 16 (08) : 1283 - 1288
  • [33] Apatinib for patients with unresectable high-grade osteosarcoma progressing after standard chemotherapy: A multi-center retrospective study.
    Yu, Wenxi
    Yu, Xiuchun
    Wu, Sujia
    Tang, Lina
    Zheng, Shui'er
    Zhou, Yan
    Huang, Yujing
    Qian, Guowei
    Li, Hongtao
    Zhang, Jianjun
    He, Aina
    Wang, Yonggang
    Hu, Haiyan
    Lin, Feng
    Shen, Zan
    Yao, Yang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Brief high-dose methotrexate-based chemotherapy (HDMVP) without radiation results in prolonged event-free and overall survival in primary central nervous system lymphoma (PCNSL)
    Cheung, M
    Mangel, J
    Hicks, L
    Buckstein, R
    Berinstein, N
    Spaner, D
    Imrie, K
    Piliotis, E
    ANNALS OF ONCOLOGY, 2005, 16 : 167 - 167
  • [35] A comment and update on "Does the histological subtype of high-grade central osteosarcoma influence the response to treatment with chemotherapy and does it affect overall survival? A study on 570 patients of two consecutive trials of the European Osteosarcoma Intergroup"
    Bacci, G
    Ferrari, S
    Bertoni, F
    Longhi, A
    Bacchini, P
    Giacomini, S
    Forni, C
    EUROPEAN JOURNAL OF CANCER, 2003, 39 (04) : 548 - 549
  • [36] The Use of Recombinant Erythropoietin for the Treatment of Chemotherapy-Induced Anemia in Patients With Ovarian Cancer Does Not Affect Progression-Free or Overall Survival
    Cantrell, Leigh A.
    Westin, Shannon N.
    Van Le, Linda
    CANCER, 2011, 117 (06) : 1220 - 1226
  • [37] Outcomes of event-free survival in patients with Wilms tumor undergoing preoperative chemotherapy. Analysis of lymph-node yield in a single-center cohort
    Jayakumar, T. K.
    Pathak, Manish
    Sinha, Arvind
    JOURNAL OF PEDIATRIC UROLOGY, 2021, 17 (02) : 228 - 229
  • [38] Impact of chemotherapy-induced ovarian failure (CIOF) on disease-free survival (DFS) and overall survival (OS) in young women with early breast cancer (EBC)
    Furlanetto, J.
    Nekljudova, V.
    Schneeweiss, A.
    Thode, C.
    Denkert, C.
    Untch, M.
    Bassy, M.
    Karn, T.
    Fasching, P. A.
    Stickeler, E.
    Schem, C.
    Marme, F.
    Grischke, E. -M.
    van Mackelenbergh, M.
    Strik, D.
    Schmatloch, S.
    Mueller, V.
    Loibl, S.
    ANNALS OF ONCOLOGY, 2019, 30 : 57 - +
  • [39] Impact of Chemotherapy-Induced Ovarian Failure (CIOF) on Disease-Free Survival (DFS) and Overall Survival (OS) in Young Women with Early Breast Cancer (EBC)
    Furlanetto, Jenny
    Nekljudova, Valentina
    Schneeweiss, Andreas
    Thode, Christian
    Denkert, Carsten
    Untch, Michael
    Bassy, Martina
    Karn, Thomas
    Fasching, Peter A.
    Stickeler, Elmar
    Schem, Christian
    Marme, Frederik
    Grischke, Eva-Maria
    van Mackelenbergh, Marion
    Strik, Dorninika
    Schmatloch, Sabine
    Mueller, Volkmar
    Loibl, Sibylle
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 6 - 6
  • [40] Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
    Marina, Neyssa M.
    Smeland, Sigbjorn
    Bielack, Stefan S.
    Bernstein, Mark
    Jovic, Gordana
    Krailo, Mark D.
    Hook, Jane M.
    Arndt, Carola
    van den Berg, Henk
    Brennan, Bernadette
    Brichard, Benedicte
    Brown, Ken L. B.
    Butterfass-Bahloul, Trude
    Calaminus, Gabriele
    Daldrup-Link, Heike E.
    Eriksson, Mikael
    Gebhardt, Mark C.
    Gelderblom, Hans
    Gerss, Joachim
    Goldsby, Robert
    Goorin, Allen
    Gorlick, Richard
    Grier, Holcombe E.
    Hale, Juliet P.
    Hall, Kirsten Sundby
    Hardes, Jendrik
    Hawkins, Douglas S.
    Helmke, Knut
    Hogendoorn, Pancras C. W.
    Isakoff, Michael S.
    Janeway, Katherine A.
    Juergens, Heribert
    Kager, Leo
    Kuhne, Thomas
    Lau, Ching C.
    Leavey, Patrick J.
    Lessnick, Stephen L.
    Mascarenhas, Leo
    Meyers, Paul A.
    Mottl, Hubert
    Nathrath, Michaela
    Papai, Zsuzsanna
    Randall, R. Lor
    Reichardt, Peter
    Renard, Marleen
    Safwat, Akmal Ahmed
    Schwartz, Cindy L.
    Stevens, Michael C. G.
    Strauss, Sandra J.
    Teot, Lisa
    LANCET ONCOLOGY, 2016, 17 (10): : 1396 - 1408